Sulik A, Kowal-Bielecka O, Domysławska I, Chwiećko J, Sierakowski S
Department of Rheumatology and Internal Diseases, Medical University of Białystok, Poland.
Rocz Akad Med Bialymst. 2005;50 Suppl 1:228-31.
The aim of our study was to evaluate the prevalence of anticardiolipin and anti-beta2-glikoprotein I (anti-beta2GPI) antibodies in patients with systemic sclerosis (SSc) and to correlate the presence of these antibodies with clinical and serological features of the disease.
22 patients (21 women and 1 man) fulfilling the ACR classification criteria of SSc were included into the study. In all SSc patients a detailed clinical evaluation including skin and internal organ involvement was performed. Moreover, the measurements of antitopoisomerase I (anti-Scl-70) and anticentromere (ACA) antibodies were done in all patients studied. Anticardiolipin antibodies in IgM and IgG class and anti-beta2GPI antibodies in IgM, IgG and IgA class were evaluated using ELISA kits (Hycor Biomedical and DiaSorin).
Anticardiolipin antibodies were found in 10/22 (45.5%) patients with SSc, in 6/12 (50%) with diffuse SSc and in 4/10 (40%) with the limited SSc. Anticardiolipin antibodies in the IgG class were observed in 4/22 (18.2%) patients, and in the IgM class in 9/22 (40.9%) subjects. Anti-beta2GPI antibodies were found in 9/22 patients (40.9%), of which 3/22 (13.6%) had antibodies in IgG class, 4/22 (18.2%) in IgM class and 3/22 (13.6%) in the IgA class. Anti-beta2GPI antibodies were found exclusively in the patients in whom the anticardiolipin antibodies were also present. An association between the presence of antiphospholipid antibodies and internal organ involvement (pulmonary fibrosis, pulmonary hypertension and the alterations of oesophageal function) was not significant. No significant correlation was found between the presence of anticardiolipin or anti-beta2GPI antibodies and the presence of anti-Scl-70 or ACA antibodies.
The results of our study indicate that the prevalence of anticardiolipin antibodies and anti-beta2GPI antibodies is relatively high in patients with SSc. A more detailed assessment of the relationship between the presence of antiphospholipid antibodies and the clinical and serological features of SSc requires further studies on the larger group of patients and a several years of follow-up.
本研究旨在评估系统性硬化症（SSc）患者中抗心磷脂抗体和抗β2糖蛋白I（抗β2GPI）抗体的患病率，并将这些抗体的存在与疾病的临床和血清学特征相关联。
22例符合美国风湿病学会（ACR）SSc分类标准的患者（21名女性和1名男性）纳入本研究。对所有SSc患者进行了包括皮肤和内脏器官受累情况的详细临床评估。此外，对所有研究患者进行了抗拓扑异构酶I（抗Scl - 70）和抗着丝点（ACA）抗体检测。使用酶联免疫吸附测定试剂盒（Hycor Biomedical和DiaSorin）评估IgM和IgG类抗心磷脂抗体以及IgM、IgG和IgA类抗β2GPI抗体。
在22例SSc患者中，10例（45.5%）检测到抗心磷脂抗体，其中弥漫性SSc患者中6例（50%），局限性SSc患者中4例（40%）。4例（18.2%）患者检测到IgG类抗心磷脂抗体，9例（40.9%）患者检测到IgM类抗心磷脂抗体。9例（40.9%）患者检测到抗β2GPI抗体，其中3例（13.6%）为IgG类抗体，4例（18.2%）为IgM类抗体，3例（13.6%）为IgA类抗体。抗β2GPI抗体仅在同时存在抗心磷脂抗体的患者中发现。抗磷脂抗体的存在与内脏器官受累（肺纤维化、肺动脉高压和食管功能改变）之间无显著相关性。抗心磷脂或抗β2GPI抗体的存在与抗Scl - 70或ACA抗体的存在之间未发现显著相关性。
我们的研究结果表明，SSc患者中抗心磷脂抗体和抗β2GPI抗体的患病率相对较高。需要对更大规模的患者群体进行进一步研究并进行数年随访，以更详细地评估抗磷脂抗体的存在与SSc临床和血清学特征之间的关系。
